This page lists past opportunities from CIP.
Requests for Application (RFA) are usually announced with special application dates; there is no possibility for applying after that date. Program Announcements (PA, PAR) may be open for a set period of time, such as 3 years or less; applications submitted in response to Program Announcements may be due on the standard dates (February 1, June1, and October 1) or may have special dates for receipt of applications. Please pay attention to these dates. Contact a CIP staff member if you have questions.
Anne E. Menkens, Ph.D. (email@example.com) at 301-435-9024
The Biomedical Imaging Program (CIP), of the Division of Cancer Treatment and Diagnosis (DCTD) solicits exploratory/developmental (R21) grants that articulate highly innovative research concepts in diagnostic cancer imaging. Within each area of importance in imaging, there exists a need for innovative and creative approaches leading to new avenues of research. One way to encourage research into high risk/high impact areas is to provide investigators with the initial resources required to accomplish feasibility and pilot testing of innovative ideas. The R21 mechanism will provide investigators at all career levels with a defined level of funding adequate for the initial feasibility testing of high risk/high impact concepts and, if the concepts are viable, for the generation of experimental preliminary data. This would render the investigators competitive for continued funding through other NIH research award mechanisms, thus potentially leading to the establishment of new research programs in areas that might have previously remained unexplored.
See full description in NIH Guide:PA-01-030
Barbara Y. Croft, Ph.D. (firstname.lastname@example.org) at 301-496-9531
Support both: (a) inter-disciplinary shared imaging research resources to be used by cancer investigators and (b) research related to small animal imaging technology.
See full description in NIH Guide:NCI/CIP RFA: CA-01-012
Grants are designed to support inter-disciplinary centers for functional imaging research (imaging sciences, chemistry, radiopharmaceutical chemistry, cell and molecular biology, pharmacology, computer science and biomedical engineering).
See full description in NIH Guide:RFA: CA-01-010
The National Cancer Institute (NCI) invites applications on the development of novel image acquisition or enhancement methods, incorporating limited pilot or feasibility evaluations using either pre-clinical models or clinical studies. This initiative is intended to facilitate the development of novel imaging technologies for early detection, screening, diagnosis and image guided treatment of cancer and other diseases. The intent is to stimulate: (a) the development of highly innovative image acquisition and enhancement methods, including high risk/high gain research on technologies that exploit our knowledge of the molecular basis of cancer or other disease, and (b) the integration of these emerging technologies with traditional imaging methods for more effective solutions for health care delivery. A phased innovation award mechanism (R21/R33) is proposed that is more suitable for supporting imaging technology development. Applications from academia, industry and the use of the SBIR/STTR funding mechanisms are encouraged.
See full description in NIH Guide:PAR-00-090
The National Cancer Institute (NCI) invites applications from investigators who are interested in joining a consortium of institutions to develop the necessary consensus and standards for an image database resource and to construct a database of spiral computed tomography (CT) lung images. There is considerable interest in using spiral CT lung scanning for lung cancer screening for patients at high risk. Early detection and intervention may significantly reduce lung cancer mortality rates. The use of image processing methods may be an important adjunct to facilitate spiral CT lung cancer screening. Investigators developing image-processing algorithms need standardized databases with which to work. The generation of standardized databases requires the development of consensus on many issues related to database design, accessibility, metrics and statistical methods for evaluating image-processing algorithms. NCI therefore plans to establish a consortium of institutions, called the Lung Image Database Consortium (LIDC), to develop such consensus and the necessary database.
See full description in NIH Guide:RFA: CA-01-001
Integrate hardware, software and psychophysics research to optimize displays for digital mammography.
See full description in NIH Guide:PA-99-082
See full description in NIH Guide:PA-99-083
Grants are designed to support the development, risk assessment, and application of improved imaging methods for the localization, biopsy and image guided biopsy or therapy of prostate cancer. Relevant investigations could include technology development, in vitro laboratory work, pre-clinical animal studies, or early feasibility testing in humans depending on the maturity of the methods proposed, or evaluation of the effects of age-associated changes and co-morbid conditions as they affect imaging diagnosis and treatment techniques.
See full description in NIH Guide:RFA: CA-99-015
See full description in NIH Guide:PAR-99-149 (SBIR/STTR)
Support for development and application of labeled therapeutic agents as compounds for imaging studies, and/or metabolic markers of response to therapeutic agents.
See full description in NIH Guide:RFA: CA-98-024
Establish a single national Network of investigators to perform multi-institutional clinical trials in diagnostic imaging.
Contact ACRIN for proposed imaging protocols
See full description in NIH Guide:RFA: CA-97-020
Anne E. Menkens, Ph.D. (email@example.com) at 301-435-9024
Exploratory/development grants (high risk/high impact) that articulate highly innovative research concepts in diagnostic cancer imaging; i.e. generate experimental preliminary data for R01 funding for both new and established investigato
See full description in NIH Guide:PA-98-008